Evidence map›Paper›PMID 32826298›Full record

Observational studyNeurology(R) neuroimmunology & neuroinflammation2020

CSF neurofilament light chain testing as an aid to determine treatment strategies in MS.

Saúl Reyes, Ide Smets, David Holden, Karina Carrillo-Loza, Tatiana Christmas, Lucia Bianchi, Francesca Ammoscato, Benjamin Turner, Monica Marta, Klaus Schmierer and 2 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Neurology(R) neuroimmunology & neuroinflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Current use of fluid biomarkers as outcome measures in Multiple Sclerosis (MS): a review of ongoing pharmacological clinical trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. CSF neurofilament light chain predicts 10-year clinical and radiologic worsening in multiple sclerosis.Multiple sclerosis journal - experimental, translational and clinical · 2021
    Article
  13. Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients.Therapeutic advances in neurological disorders · 2021
    Article
  14. Review
  15. Is CSF neurofilament light chain measurement relevant for MS?Neurology(R) neuroimmunology & neuroinflammation · 2020
    Article
  16. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Saúl ReyesFrom the The Blizard Institute (S.R., I.S., D.H., K.C.-L., T.C., L.B., F.A., M.M., K.S., G.G., S.G.), Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London; and Clinical Board Medicine (Neuroscience) (S.R., I.S., B.T., M.M., K.S., G.G., S.G.), The Royal London Hospital, Barts Health NHS Trust, London, UK.ORCID 0000-0002-3230-3263
Ide SmetsFrom the The Blizard Institute (S.R., I.S., D.H., K.C.-L., T.C., L.B., F.A., M.M., K.S., G.G., S.G.), Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London; and Clinical Board Medicine (Neuroscience) (S.R., I.S., B.T., M.M., K.S., G.G., S.G.), The Royal London Hospital, Barts Health NHS Trust, London, UK.ORCID 0000-0001-8174-2898
David HoldenFrom the The Blizard Institute (S.R., I.S., D.H., K.C.-L., T.C., L.B., F.A., M.M., K.S., G.G., S.G.), Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London; and Clinical Board Medicine (Neuroscience) (S.R., I.S., B.T., M.M., K.S., G.G., S.G.), The Royal London Hospital, Barts Health NHS Trust, London, UK.
Karina Carrillo-LozaFrom the The Blizard Institute (S.R., I.S., D.H., K.C.-L., T.C., L.B., F.A., M.M., K.S., G.G., S.G.), Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London; and Clinical Board Medicine (Neuroscience) (S.R., I.S., B.T., M.M., K.S., G.G., S.G.), The Royal London Hospital, Barts Health NHS Trust, London, UK.
Tatiana ChristmasFrom the The Blizard Institute (S.R., I.S., D.H., K.C.-L., T.C., L.B., F.A., M.M., K.S., G.G., S.G.), Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London; and Clinical Board Medicine (Neuroscience) (S.R., I.S., B.T., M.M., K.S., G.G., S.G.), The Royal London Hospital, Barts Health NHS Trust, London, UK.
Lucia BianchiFrom the The Blizard Institute (S.R., I.S., D.H., K.C.-L., T.C., L.B., F.A., M.M., K.S., G.G., S.G.), Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London; and Clinical Board Medicine (Neuroscience) (S.R., I.S., B.T., M.M., K.S., G.G., S.G.), The Royal London Hospital, Barts Health NHS Trust, London, UK.
Francesca AmmoscatoFrom the The Blizard Institute (S.R., I.S., D.H., K.C.-L., T.C., L.B., F.A., M.M., K.S., G.G., S.G.), Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London; and Clinical Board Medicine (Neuroscience) (S.R., I.S., B.T., M.M., K.S., G.G., S.G.), The Royal London Hospital, Barts Health NHS Trust, London, UK.
Benjamin TurnerFrom the The Blizard Institute (S.R., I.S., D.H., K.C.-L., T.C., L.B., F.A., M.M., K.S., G.G., S.G.), Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London; and Clinical Board Medicine (Neuroscience) (S.R., I.S., B.T., M.M., K.S., G.G., S.G.), The Royal London Hospital, Barts Health NHS Trust, London, UK.
Monica MartaFrom the The Blizard Institute (S.R., I.S., D.H., K.C.-L., T.C., L.B., F.A., M.M., K.S., G.G., S.G.), Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London; and Clinical Board Medicine (Neuroscience) (S.R., I.S., B.T., M.M., K.S., G.G., S.G.), The Royal London Hospital, Barts Health NHS Trust, London, UK.ORCID 0000-0002-5464-9070
Klaus SchmiererFrom the The Blizard Institute (S.R., I.S., D.H., K.C.-L., T.C., L.B., F.A., M.M., K.S., G.G., S.G.), Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London; and Clinical Board Medicine (Neuroscience) (S.R., I.S., B.T., M.M., K.S., G.G., S.G.), The Royal London Hospital, Barts Health NHS Trust, London, UK.ORCID 0000-0002-9293-8893
Gavin GiovannoniFrom the The Blizard Institute (S.R., I.S., D.H., K.C.-L., T.C., L.B., F.A., M.M., K.S., G.G., S.G.), Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London; and Clinical Board Medicine (Neuroscience) (S.R., I.S., B.T., M.M., K.S., G.G., S.G.), The Royal London Hospital, Barts Health NHS Trust, London, UK.
Sharmilee GnanapavanFrom the The Blizard Institute (S.R., I.S., D.H., K.C.-L., T.C., L.B., F.A., M.M., K.S., G.G., S.G.), Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London; and Clinical Board Medicine (Neuroscience) (S.R., I.S., B.T., M.M., K.S., G.G., S.G.), The Royal London Hospital, Barts Health NHS Trust, London, UK. s.gnanapavan@qmul.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the use of CSF neurofilament light chain (NfL) measurements in clinical practice as well as their effect on treatment strategies and outcomes in patients with MS.

methodsThis was an observational cohort study of patients with MS who had a CSF NfL measurement between December 2015 and July 2018 as part of their routine clinical care. Treatment strategies were classified as "No Treatment/No Escalation" (no treatment or no escalation of treatment) or "Treatment/Escalation" (first-line injectable/oral disease-modifying therapies (DMTs), highly active DMTs, or treatment escalation). Change in Expanded Disability Status Scale (EDSS) scores was evaluated after 1-year follow-up.

resultsOf 203 patients with MS, 117 (58%) had relapsing-remitting MS. Disease activity was most frequently indicated by elevated CSF NfL (n = 85), followed by clinical (n = 81) and MRI activity (n = 65). CSF NfL measurements were independently associated with clinical (

conclusionsCSF NfL measurements informed treatment strategies, alongside clinical and MRI measures. CSF NfL levels were the only indicator of disease activity in a subset of patients, which was more pronounced in patients with PMS. Elevated CSF NfL was associated with more Treatment/Escalation strategies, which had an impact on EDSS outcomes at 1 year.

Indexed as

AdultDisease ProgressionFemaleFollow-Up StudiesHumansImmunologic FactorsMaleMiddle AgedMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Relapsing-RemittingNeurofilament ProteinsOutcome Assessment, Health CareImmunologic Factorsneurofilament protein LNeurofilament Proteins

Identifiers

PMID32826298
PMCPMC7455313

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.